To date, the cocktail of nivolumab (anti-PD1 antibody) and ipilimumab (anti-CTLA-4 antibody) was the first approved and remains the only anti-ICM antibody combination approved in the clinic as first-line treatment for untreated patients with metastatic melanoma. Here, CTLA4 is linked to metastatic melanoma.